Welcome to our dedicated page for Bed Bath & Beyond SEC filings (Ticker: BBBY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bed Bath & Beyond, Inc. (NYSE: BBBY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and related exhibits. These filings offer detailed insight into Bed Bath & Beyond’s strategy as an ecommerce-focused "Everything Home" company with home retail brands and a blockchain asset portfolio.
In its Form 8-K filings, Bed Bath & Beyond reports on a range of material events. These include merger and acquisition agreements, such as the Agreement and Plan of Merger under which a wholly owned subsidiary of Bed Bath & Beyond will merge with The Brand House Collective, Inc., subject to customary closing conditions. The filing describes the exchange ratio, treatment of equity awards, conditions to closing, termination rights, and potential termination fees, giving investors a structured view of the proposed transaction.
Other 8-Ks detail credit and financing arrangements, including an Amended and Restated Term Loan Credit Agreement and subsequent amendments with The Brand House Collective, delayed-draw term loan commitments that are convertible into equity, and additional commitments disclosed in later amendments. Filings also describe Bed Bath & Beyond’s participation in loans issued by The Container Store, Inc. via participation agreements, outlining aggregate purchase prices and the rights to interest and repayment associated with these positions.
Capital markets actions are another key focus of the company’s SEC disclosures. Bed Bath & Beyond has filed materials related to a warrant dividend distribution to shareholders, including a Warrant Agreement, registration statements for shares issuable upon exercise of the warrants, and detailed terms covering exercise price, expiration, early expiration conditions, and listing applications for the warrants under the ticker BBBY WS.
Filings further cover corporate governance and compensation matters, such as the adoption of the 2025 Employment Inducement Equity Incentive Plan under NYSE Rule 303A.08, and the appointment of Marcus Lemonis as Chief Executive Officer in addition to his role as Executive Chairman and principal executive officer. Results of operations and financial condition are furnished through earnings-related 8-Ks, which reference press releases and presentations with quarterly financial data and key operating metrics.
On Stock Titan, these filings are updated as they are released on EDGAR. AI-powered summaries help explain the significance of each document, from merger agreements and credit amendments to warrant distributions and executive appointments, so users can more quickly understand how each filing relates to Bed Bath & Beyond’s home-focused retail, services, and blockchain strategy.
Bed Bath & Beyond, Inc. announced a warrant dividend to its common shareholders. Investors of record as of the close of business on October 2, 2025 will receive warrants to purchase additional common shares.
Each holder will receive one warrant for every ten shares of common stock, rounded down, with an exercise price of $15.50 per share. The warrants are expected to be distributed on or around October 7, 2025 and will expire on October 7, 2026. The company intends to apply to list the warrants on the New York Stock Exchange under the symbol BBBYW, allowing them to trade separately.
The company plans to file a Form 8-A registration statement and a prospectus supplement describing the warrant terms, and it has posted a detailed FAQ for investors. The communication clarifies that the warrant dividend itself is not an offer or sale of securities under the Securities Act.
Brand House Collective, Inc. (TBHC) disclosed an amendment to a Schedule 13D showing Bed Bath & Beyond, Inc. beneficially owns 13,404,280 shares, representing 49.8% of the outstanding common stock based on 22,461,383 shares outstanding as of September 9, 2025. Bed Bath & Beyond amended its credit arrangements with the issuer on September 15, 2025, by committing to $20.0 million of delayed-draw term loan commitments evidenced by convertible Delayed Draw Notes. The Delayed Draw Notes and existing Notes can convert into 4,469,815 shares currently exercisable, equal to 19.9% of outstanding shares. The credit amendments also adjust a change-of-control threshold from 65% to 75%.